Preclinical: ​ATNM-400 advances to clinical stage with very good preclinical results for tumors not expressing PSMA

[Maxone73]

​ATNM-400 is an innovative radiotherapy for advanced prostate cancer that utilizes Actinium-225 and targets a marker other than PSMA (still undisclosed, but there will be a presentation by the end of April).

In preclinical studies, a single dose achieved up to 99.8% tumor growth inhibition, with selective accumulation in tumors for up to 144 hours and minimal impact on healthy tissues.

These promising results suggest ATNM-400 could offer a new treatment avenue for patients unresponsive to existing PSMA-targeted therapies.

prostatewarriors.com/2025/0...

[PCaWarrior]

Target might be disclosed later this year.

The exact dates for ATNM-400's clinical trial initiation or completion have not been disclosed, the company's infrastructure development and preclinical progress suggest trials may begin shortly after the AACR presentation, with initial results anticipated later in 2025.